Category: Diabetes/Prediabetes/Hypoglycemia

Monitor: 17


Thursday, Apr 25
12:00 PM – 12:30 PM

Objective : To evaluate clinical outcomes of treatment with Sitagliptin in patients with type 2 diabetes mellitus (T2DM) from Pan India

Methods : The current study is a retrospective data analysis from multiple centers of Apollo Sugar Clinics initiated on treatment with Sitagliptin a DPP4 inhibitor as add-on to other anti-diabetes drugs. A total of 6762 patients initiated on DPP4 inhibitors therapy were registered in electronic medical records (EMR) of Apollo Sugar was used for this analysis. Demographics and baseline characteristics were captured in EMR database. Descriptive statistics were applied to calculate mean (standard deviation) and frequency (percentage) for continuous and discrete variables and appropriate statistical test was used to test for the significance (p ≤0.05).

Results : Of the total 6762 DPP4 inhibitors prescriptions, 2248 (33%) were on Sitagliptin, of which patients (N=1146) with follow up data were included in the analysis. The mean age of these patients was 53.7 years, 737 (64%) were males and 409 (36%) were females. Of these prescriptions, 759 (66%) were in combination with other oral drugs and 387 (34%) were in combination with Insulin. At initiation mean HbA1c was 8.6%, fasting (FBG) and post-prandial blood glucose (PPBG) was 184 mg/dL and 271 mg/dL, respectively and the mean BMI was 27.5 kg/m2. At follow up the mean HbA1c was 8.1%, with a mean change of 0.5%, and FBG and PPBG reduced to 165 mg/dL and 244 mg/dL, respectively. Among these 336 (44%) patients were at target HbA1c -0.5%, respectively. The percentage of patients at target HbA1c <7% was greater in Sitagliptin along with other orals (37%) compared to Sitagliptin with insulin (15%).  

Discussion : The analysis shows Sitagliptin could be choice of treatment as there was clinically considerable reduction in HbA1c, and more than 1/3rd of the patients were at target. Compared to treatment of Sitagliptin along with insulin patients at target HbA1c <7% were higher in combination with other orals antidiabetes drugs. 

Conclusion : DPP4i Sitagliptin is the second highly prescribed drug in real clinical practice. It is a clinically effective drug as most of the patients on treatment achieved HbA1c goals. 


Manikandan RM

Consultant Endocrinologist & Diabetologist
Apollo Sugar Clinics, Apollo Hospital, India


Dwarakanath CS

Senior Endocrinologist
Apollo Sugar Clinic, Apollo Hospital, India

Dr. Dwarakanath C.S. is a Endocrinologist in Basavanagudi, Bangalore and has an experience of 31 years in this field. Dr. Dwarakanath C.S. practices at Surya Endocrine Diabetes Centre in Basavanagudi, Bangalore, Surya Endocrine Diabetes Centre in Nagarbhavi, Bangalore and Apollo Sugar Clinic in Bannerghatta Road, Bangalore. Completed MBBS from JJMMC, Davanagere in 1984,MD - Medicine from Mysore Medical College, Mysore in 1988 and DM - Endocrinology from All India Institutes of Medical Sciences, AIIMS, New Delhi in 1996. Member of Karnataka Medical Council and Indian Medical Association (IMA).

Venkataraman S

Senior Consultant Diabetologist
Apollo Sugar Clinic, Apollo Hospital, India

Dr. S. Venkataraman is a Sr. Consultant Diabetologist practicing at Apollo Sugar Clinics, Greamsroad Chennai. He is a highly experienced diabetologist with more than 25 years of experience in treating all types of diabetes. Over the years, he has numerous publications to his credit. Apart from that, he has huge academic experience as a Professor of Diabetology and has taught in Madurai Medical College, and Rajaji Hospital, Maduria, and Madras Medical College. He received an award from IDF (International Diabetes Federation) for his paper on Pregnancy and Diabetes.

Narayanan NK

Sr. Consultant Endocrinologist and Diabetes Specialist
Apollo Sugar Clinic, Apollo Hospital, India


Usha Ayyagari

Senior Consultant Endocrinologist and Diabetes Specialist
Apollo Sugar Clinic, Apollo Hospital, India


Boochandran TS

Senior Endocrinologist
Apollo Sugar Clinic, Apollo Hospital, India


Shantharam Duvuru

Senior Diabetologist
Apollo Sugar Clinic, Apollo Hospital, India


Jayashree Gopal

Endocrinologist and Diabetologist
Apollo Sugar Clinic, Apollo Hospital, India


Vamsi Krishna Kolukula

Head, Clinical Excellence
Apollo Sugar Clinics Limited., India


Shashank Joshi

Senior Endocrinologist
Lilavati and Bhatia Hospital
Mumbai, Maharashtra, India

Prof Shashank R. Joshi MD, DM, FACP, FACE, FRCP
Endocrinologist, Lilavati & Bhatia Hospital
Consultant and Advisor, Apollo Sugar Clinics
President, Indian Academy of Diabetes, Past President, Endocrine Society of India
Past President, Research Society for Study of Diabetes in India(RSSDI)
Past President, All India Association for Advancement of Research in Obesity Past President, Association of Physicians of India, Emeritus Editor, JAPI
Indian Chapter Chair, AACE
He was honored by the Government of India, in 2014, by bestowing on him the Padma Shri, the fourth highest civilian award, for his services to the field of medicine. He is also a recipient of the International Clinician Award, received at the 21st American Association of Clinical Endocrinologists (AACE) Annual Scientific and Clinical Congress, Philadelphia. This is an annual award given to practicing endocrinologists, outside the US